Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Fulminant acute myocarditis in the Cardiac Intensive Care Unit – a long but successful road to recovery
Session:
SESSÃO DE COMUNICAÇÕES ORAIS 04 - INOVAÇÃO EM CUIDADOS INTENSIVOS: NOVAS INTERVENÇÕES EM CHOQUE CARDIOGÉNICO E SÍNDROMAS CORONÁRIAS AGUDAS
Speaker:
Rita Amador
Congress:
CPC 2025
Topic:
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
Theme:
14. Acute Cardiac Care
Subtheme:
14.4 Acute Cardiac Care – Cardiogenic Shock
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Rita Amador; Ana Rita Bello; Rita Lima; Rita Carvalho; Joana Certo Pereira; Rita Barbosa; Débora Correia; João Presume; Jorge Ferreira; Christopher Strong; Catarina Brízido; António Tralhão
Abstract
<p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Background and Aim</strong><br /> Fulminant myocarditis leading to cardiogenic shock (CS) is a life-threatening condition arising from various inflammatory etiologies. This study aims to describe the clinical characteristics, management strategies, and outcomes of patients with myocarditis-related CS treated at a tertiary center with mechanical circulatory support (MCS) capabilities.</span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Methods</strong><br /> We conducted a retrospective, observational single-center study of consecutive patients (pts) admitted to our Cardiac Intensive Care Unit for CS-related myocarditis, between 2018 and 2024. Diagnostic confirmation was made through cardiac magnetic resonance imaging (CMR) or endomyocardial biopsy (EMB), while a presumed diagnosis was considered based on clinical, laboratorial and TTE features in the absence of coronary artery disease.</span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Results</strong><br /> Fourteen pts (mean age 45 ± 14 years, 64% male) were included. The majority (93%, n = 13) experienced their first myocarditis episode.</span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">The most common symptom at admission was chest pain (57%, n = 8), while 29% (n=4) immediately presented in CS. The median time from initial symptom onset to CS was 5 days (IQR 4–6). Median LVEF at admission was 25 (IQR 20 – 34)%, and biventricular dysfunction was present in 57% (n=8). Diagnosis was confirmed by EMB (diagnostic yield 80%) or CMR in 13 pts, while 1 was diagnosed presumptively.</span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">SCAI class at admission was C in 9 pts (64%), D in 4 (29%) and E in1 pt (7%), with 5 pts deteriorating over the first 24 hours. All pts required vasoactive pharmacological support, and 71% (n = 10) required MCS, mostly VA-ECMO (n=9). Other interventions included non-invasive and invasive mechanical ventilation (71%, n=10) and renal replacement therapy (21%, n = 3). Complete AV block occurred in 14% (n = 2) of patients, 21% (n = 3) had ventricular arrythmias and 1 patient (7%) had cardiac tamponade requiring pericardiocentesis. </span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">The ICU length-of-stay was 12 days (IQR 7 – 21), and total hospital admission was 32 days (IQR 20–47). In-hospital mortality was 14% (n = 2): one due to refractory shock and another for surgical LVAD-related complications. One patient underwent transplantation for unrecovered biventricular failure. Among survivors (n = 11), LVEF improvement was observed at discharge (51 (IQR 41 – 56)%; p < 0.001), with 64% (n = 7) normalizing LVEF (>50%).</span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">During a median follow-up of 20 months (IQR 5–35), one patient died of non-cardiovascular causes, and another underwent transplantation for persistent heart failure. The remaining patients (n = 8) were in NYHA class I or II, and all maintaining LVEF >50%.</span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Conclusions</strong><br /> Fulminant myocarditis carries significant acute morbidity and mortality and often requires MCS as a bridge-to-recovery. However, survivors demonstrate favorable long-term outcomes, including functional recovery and LVEF normalization. Further studies are needed to optimize support strategies and improve outcomes in this high-risk population.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site